Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on March 9, 2017. The filing serves to incorporate a specific agreement by reference into the company's Registration Statement on Form F-10 (File No. 333-206994). The document does not cover a specific financial reporting period but rather discloses a corporate transaction.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a contractual agreement and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed is the execution of a Manufacturing Collaboration and Services Agreement dated November 22, 2016, between Aurinia Pharmaceuticals Inc. and Lonza Ltd. This agreement is included as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard incorporation of the manufacturing agreement. No unusual items or contingencies are detailed in the provided text.
Key Facts for Investor Verification
- Verify the terms of the Manufacturing Collaboration and Services Agreement with Lonza Ltd. dated November 22, 2016 (Exhibit 99.1).
- Confirm the impact of this agreement on the company's Registration Statement on Form F-10 (File No. 333-206994).
- Note that this filing does not contain updated financial results or operational metrics.